One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Pulmonary Rehabilitation after a Chronic Obstructive Pulmonary Disease Exacerbation: Impact on Readmission Risk in a Real-World Setting
Linda Nici
doi : 10.1164/rccm.202107-1768ed
Volume 204, Issue 9, pp. 1005–1006
The Renin–Angiotensin–Aldosterone System in COVID-19–related and Non–COVID-19–related Acute Respiratory Distress Syndrome: Not So Different after All?
Sean P. Collins 1, Mark C. Chappell 2, and D. Clark Files 3
doi : 10.1164/rccm.202108-1904ed
Volume 204, Issue 9, pp. 1007–1008
Metabolic Risk Factors and the Development of World Trade Center Lung Disease
Fernando Holguin
doi : 10.1164/rccm.202108-1824ed
Volume 204, Issue 9, pp. 1008–1010
Small Airways in Idiopathic Pulmonary Fibrosis: Quiet but Not Forgotten
Toby M. Maher
doi : 10.1164/rccm.202108-2007ed
Volume 204, Issue 9, pp. 1010–1011
Breathing Hope into Directed Therapy for Pulmonary Infections
Grant Waterer
doi : 10.1164/rccm.202108-1809ed
Volume 204, Issue 9, pp. 1011–1013
Individualized Treatment Duration in Tuberculosis Treatment: Precision versus Simplicity
Menonli Adjobimey 1,2, Marcel A. Behr 3,4,5, and Dick Menzies 3,4,5
doi : 10.1164/rccm.202107-1744ed
Volume 204, Issue 9, pp. 1013–1014
Association between Initiation of Pulmonary Rehabilitation and Rehospitalizations in Patients Hospitalized with Chronic Obstructive Pulmonary Disease
Mihaela S. Stefan 1,2, Penelope S. Pekow 1,3, Aruna Priya 1,3, Richard ZuWallack 4, Kerry A. Spitzer 1, Tara C. Lagu 5,6, Quinn R. Pack 1,2,7, Victor M. Pinto-Plata 2,8, Kathleen M. Mazor 9, and Peter K. Lindenauer 1,2,10
doi : 10.1164/rccm.202012-4389oc
Volume 204, Issue 9, pp. 1015–1023
Although clinical trials have found that pulmonary rehabilitation (PR) can reduce the risk of readmissions after hospitalization for a chronic obstructive pulmonary disease (COPD) exacerbation, less is known about PR’s impact in routine clinical practice.
Increased Angiotensin-Converting Enzyme 2 and Loss of Alveolar Type II Cells in COVID-19–related Acute Respiratory Distress Syndrome
Ludovic Gerard 1,2, Marylene Lecocq 2, Caroline Bouzin 3, Delphine Hoton 4, Gregory Schmit 4, Joao Pinto Pereira 1, Virginie Montiel 1, Thomas Plante-Bordeneuve 2, Pierre-François Laterre 1, and Charles Pilette 2,5
doi : 10.1164/rccm.202012-4461oc
Volume 204, Issue 9, pp. 1024–1034
ACE2 (angiotensin-converting enzyme 2), the entry receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is expressed in type 2 alveolar epithelial cells (AT2) that may play key roles in postinjury repair. An imbalance between ACE2 and ACE has also been hypothesized to contribute to lung injury.
Dynamic Metabolic Risk Profiling of World Trade Center Lung Disease: A Longitudinal Cohort Study
Sophia Kwon 1*, Myeonggyun Lee 2*, George Crowley 1, Theresa Schwartz 3, Rachel Zeig-Owens 3,4, David J. Prezant 3,5, Mengling Liu 2,6, and Anna Nolan 1,3,6
doi : 10.1164/rccm.202006-2617oc
Volume 204, Issue 9, pp. 1035–1047
Metabolic syndrome (MetSyn) increases the risk of World Trade Center (WTC) lung injury (LI). However, the temporal relationship of MetSyn, exposure intensity, and lung dysfunction is not well understood.
Small Airway Reduction and Fibrosis Is an Early Pathologic Feature of Idiopathic Pulmonary Fibrosis
Kohei Ikezoe 1, Tillie-Louise Hackett 1, Samuel Peterson 2, Dante Prins 1, Cameron J. Hague 3, Darra Murphy 3, Stacey LeDoux 1, Fanny Chu 1, Feng Xu 1, Joel D. Cooper 4, Naoya Tanabe 5, Christopher J. Ryerson 1, Peter D. Paré 1, Harvey O. Coxson 1, Thomas V. Colby 6, James C. Hogg 1, and Drago? M. Vasilescu 1
doi : 10.1164/rccm.202103-0585oc
Volume 204, Issue 9, pp. 1048–1059
To improve disease outcomes in idiopathic pulmonary fibrosis (IPF), it is essential to understand its early pathophysiology so that it can be targeted therapeutically.
Obesity-related IL-18 Impairs T-Regulatory Cell Function and Promotes Lung Ischemia–Reperfusion Injury
Tatiana Akimova 1,2, Tianyi Zhang 1,2, Lanette M. Christensen 1,2, Zhonglin Wang 3, Rongxiang Han 1,2, Dmitry Negorev 1,2, Arabinda Samanta 1,2, Isaac E. Sasson 4,5*, Trivikram Gaddapara 6, Jing Jiao 7, Liqing Wang 1,2, Tricia R. Bhatti 1,2, Matthew H. Levine 3, Joshua M. Diamond 8, Ulf H. Beier 7, Rebecca A. Simmons 6, Edward Cantu 9, David S. Wilkes 10,11‡, David J. Lederer 12§, Michaela Anderson 12, Jason D. Christie 8,9, Wayne W. Hancock 1,2
doi : 10.1164/rccm.202012-4306oc
Volume 204, Issue 9, pp. 1060–1074
Primary graft dysfunction (PGD) is a severe form of acute lung injury, leading to increased early morbidity and mortality after lung transplant. Obesity is a major health problem, and recipient obesity is one of the most significant risk factors for developing PGD.
Virus-induced Volatile Organic Compounds Are Detectable in Exhaled Breath during Pulmonary Infection
Faisal Kamal 1*, Sacheen Kumar 1,2*, Michael R. Edwards 3, Kirill Veselkov 1, Ilaria Belluomo 1, Tatiana Kebadze 3, Andrea Romano 1, Maria-Belen Trujillo-Torralbo 3, Tasnim Shahridan Faiez 4, Ross Walton 3, Andrew I. Ritchie 3, Dexter J. Wiseman 3, Ivan Laponogov 1, Gavin Donaldson 3‡, Jadwiga A. Wedzicha 3‡, Sebastian L. Johnston 3, Aran Singanayagam 4*, and George B. Hanna 1*
doi : 10.1164/rccm.202103-0660oc
Volume 204, Issue 9, pp. 1075–1085
Chronic obstructive pulmonary disease (COPD) is a condition punctuated by acute exacerbations commonly triggered by viral and/or bacterial infection. Early identification of exacerbation triggers is important to guide appropriate therapy, but currently available tests are slow and imprecise. Volatile organic compounds (VOCs) can be detected in exhaled breath and have the potential to be rapid tissue-specific biomarkers of infection etiology.
Precision-Enhancing Risk Stratification Tools for Selecting Optimal Treatment Durations in Tuberculosis Clinical Trials
Marjorie Z. Imperial 1,2, Patrick P. J. Phillips 2,3, Payam Nahid 2,3, and Radojka M. Savic 1,2,3
doi : 10.1164/rccm.202101-0117oc
Volume 204, Issue 9, pp. 1086–1096
No evidence-based tools exist to enhance precision in the selection of patient-specific optimal treatment durations to study in tuberculosis clinical trials.
Alternative and Complementary Treatments for Obstructive Sleep Apnea
Christopher R. Kawala , Christopher J. Humphreys , Tanya Khaper , and Clodagh M. Ryan
doi : 10.1164/rccm.202102-0452rr
Volume 204, Issue 9, pp. 1097
Bedside Detection and Follow-Up of Pulmonary Artery Stenosis after Lung Transplantation
Francesco Zarantonello 1, Nicolò Sella 2, Tommaso Pettenuzzo 1, Giulio Andreatta 2, Andrea Dell’Amore 3, Chiara Giraudo 4, Federico Rea 3, and Paolo Navalesi 1,2
doi : 10.1164/rccm.202101-0229im
Volume 204, Issue 9, pp. 1100–1102
Dramatic Ventricular Shunt Complications in Pulmonary and Critical Care Medicine
Woo Young Kim 1, IrfanAli Kugasia 2, Gregory Pearson 3, and Oleg Epelbaum 4
doi : 10.1164/rccm.202009-3611im
Volume 204, Issue 9, pp. e94–e96
Adherence to Continuous Positive Airway Pressure Hugely Improved during COVID-19 Lockdown in France
Jean-Louis Pépin 1,2*‡, Najeh Daabek 1,2*, Sébastien Bailly 1,2, Renaud Tamisier 1,2, David Attias 3§, and Atul Pathak 4,5§
doi : 10.1164/rccm.202103-0803le
Volume 204, Issue 9, pp. 1103–1106
Lung Function Levels Influence the Association between Obesity and Risk of COVID-19
Dinh S. Bui 1*, Raisa Cassim 1*, Melissa A. Russell 1, Alice Doherty 1, Adrian J. Lowe 1, Alvar Agusti 2,3,4,5, Shyamali C. Dharmage 1‡, and Caroline J. Lodge 1‡§
doi : 10.1164/rccm.202105-1100le
Volume 204, Issue 9, pp. 1106–1108
Determinants of Adolescent Lung Function in Indians: Race, Nutrition, and Systemic Inflammation
Mohit Aggarwal 1,2, Anubhuti Bansal 1,2, Bapu Koundinya Desiraju 3, Shailendra Singh 1, and Anurag Agrawal 1,2*
doi : 10.1164/rccm.202104-0879le
Volume 204, Issue 9, pp. 1109–1111
Pulmonary Hypertension: A Predictor of Lung Cancer Prognosis?
Zhenzhen Zheng 1*, Riken Chen 2,3,4,5,6*, Nuofu Zhang 2,3,4,5,6*, Chunying Zhuang 2,3,4,5,6*, Jianmin Lu 2,3,4,5,6*, Yue Zhong 2,3,4,5,6, Haimin Liu 2,3,4,5,6, and Cheng Hong 2,3,4,5,6‡
doi : 10.1164/rccm.202105-1256le
Volume 204, Issue 9, pp. 1112–1113
Reply to Zheng et al.
Bastian Eul 1, Michael Cekay 1, Khodr Tello 1, Jochen Wilhelm 1, Stefan Gattenlöhner 1, Ulf Sibelius 1, Friedrich Grimminger 1, Werner Seeger 1,2,3, Soni Savai Pullamsetti 1,2,3, and Rajkumar Savai 1,2,3,4*
doi : 10.1164/rccm.202106-1411le
Volume 204, Issue 9, pp. 1113
Erratum: Author Name Correction in “Positive End-Expiratory Pressure, Pleural Pressure, and Regional Compliance during Pronation. An Experimental Study”
doi : 10.1164/rccm.v204erratum2
Volume 204, Issue 9, pp. 1114
Erratum: Selective Modulation of the Pulmonary Innate Immune Response Does Not Change Lung Microbiota in Healthy Mice
doi : 10.1164/rccm.v204erratum3
Volume 204, Issue 9, pp. 1115
Neuroendocrine Cell Hyperplasia of Infancy (NEHI)/Hiperplasia de Celulas Neuroendocrina de la Infancia (NEHI)
doi : 10.1164/rccm.2046p15
Volume 204, Issue 9, pp. P15–P16
